Last reviewed · How we verify
Antara (fenofibrate) + Lovaza
This combination uses fenofibrate to activate PPARα and reduce triglycerides, while omega-3 fatty acids from Lovaza further lower triglycerides and reduce cardiovascular risk.
This combination uses fenofibrate to activate PPARα and reduce triglycerides, while omega-3 fatty acids from Lovaza further lower triglycerides and reduce cardiovascular risk. Used for Hypertriglyceridemia (elevated triglycerides), Dyslipidemia in patients requiring combination lipid-lowering therapy.
At a glance
| Generic name | Antara (fenofibrate) + Lovaza |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Fibrate + Omega-3 fatty acid combination |
| Target | PPARα (fenofibrate); GPR120, GPR40 (omega-3 fatty acids) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Fenofibrate is a fibrate that activates peroxisome proliferator-activated receptor alpha (PPARα), increasing lipolysis and reducing triglyceride synthesis in the liver. Lovaza (omega-3-acid ethyl esters) provides high-dose EPA and DHA, which reduce hepatic triglyceride production and increase triglyceride clearance. Together, they provide complementary mechanisms to lower elevated triglycerides and improve lipid profiles in patients with dyslipidemia.
Approved indications
- Hypertriglyceridemia (elevated triglycerides)
- Dyslipidemia in patients requiring combination lipid-lowering therapy
Common side effects
- Myalgia or muscle pain
- Elevated liver enzymes (ALT/AST)
- Gastrointestinal upset (nausea, dyspepsia)
- Headache
- Rash
- Elevated creatinine/renal effects
Key clinical trials
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL) (PHASE3)
- Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL (PHASE3)
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin (PHASE3)
- A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia (PHASE2)
- Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia (NA)
- A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™ (PHASE4)
- Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antara (fenofibrate) + Lovaza CI brief — competitive landscape report
- Antara (fenofibrate) + Lovaza updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI